{
  "id": 3070,
  "url": "https://nnemf.org/research/3070-effect-of-lansoprazole-on-the-epigastric-symptoms-of",
  "title": "Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial.",
  "authors": [
    "Hidekazu Suzuki",
    "Hiroaki Kusunoki",
    "Takeshi Kamiya",
    "Seiji Futagami",
    "Yasuharu Yamaguchi",
    "Toshihiro Nishizawa",
    "Eisuke Iwasaki",
    "Juntaro Matsuzaki",
    "Shinichi Takahashi",
    "Choitsu Sakamoto",
    "Ken Haruma",
    "Takashi Joh",
    "Keiko Asakura",
    "Toshifumi Hibi"
  ],
  "journal": "United European gastroenterology journal",
  "year": "2013",
  "doi": "10.1177/2050640613510904",
  "pmid": "24917996",
  "abstract": "BACKGROUND: Since the publication of the Rome III criteria for functional dyspepsia (FD), the evidence about the efficacy of half-dose of proton pump inhibitors for dyspepsia symptoms have been limited. OBJECTIVE: To examine the efficacy of lansoprazole for functional dyspepsia (FD) diagnosed with the Rome III criteria by the multicentre, double-blind, randomized, placebo-controlled study in Japan. METHODS: A total of 54 FD participants were randomized to lansoprazole 15 mg once daily or placebo for a 4-week double-blind treatment period. The primary efficacy endpoint was an overall dyspeptic symptom relief rate evaluated by 5-point Likert scale scores. The alteration of dyspeptic symptom scores during the study period was also assessed. RESULTS: At week 4, the overall dyspeptic symptom relief rates were higher in the lansoprazole group (30.4%) than in the placebo group (6.7%) (p = 0.045). The scores for epigastric pain (p = 0.045) and epigastric burning (p = 0.03) were significantly improved in the lansoprazole group compared to the placebo group, whereas the improvement of the scores for postprandial fullness (p = 0.81) and early satiation (p = 0.33) was not different between lansoprazole and placebo groups. CONCLUSIONS: Lansoprazole 15 mg ameliorates dyspeptic symptoms, particularly the epigastric pain syndrome-related symptoms of FD.",
  "effect": "benefit",
  "evidence": "moderate",
  "extraction": {
    "studyType": "randomized_trial",
    "studyTypeLabel": "randomized trial",
    "effectDirection": "benefit",
    "evidenceLabel": "Moderate",
    "population": "Participants with functional dyspepsia (FD) diagnosed with the Rome III criteria in Japan",
    "sampleSize": "54",
    "exposure": "4-week double-blind treatment period",
    "confidencePct": "74",
    "peerReviewed": "yes",
    "mainFindings": "At week 4, overall dyspeptic symptom relief was higher with lansoprazole 15 mg once daily (30.4%) than placebo (6.7%) (p=0.045). Epigastric pain (p=0.045) and epigastric burning (p=0.03) improved significantly versus placebo, while postprandial fullness (p=0.81) and early satiation (p=0.33) did not differ between groups.",
    "outcomes": [
      "Overall dyspeptic symptom relief rate (5-point Likert scale)",
      "Epigastric pain score",
      "Epigastric burning score",
      "Postprandial fullness score",
      "Early satiation score"
    ],
    "limitations": [
      "Small sample size (n=54)",
      "Short treatment duration (4 weeks)"
    ],
    "keywords": [
      "functional dyspepsia",
      "Rome III criteria",
      "lansoprazole",
      "proton pump inhibitor",
      "randomized",
      "double-blind",
      "placebo-controlled",
      "epigastric pain syndrome"
    ],
    "hubs": [],
    "raw": "{\n  \"study_type\": \"randomized_trial\",\n  \"exposure\": {\n    \"band\": null,\n    \"source\": null,\n    \"frequency_mhz\": null,\n    \"sar_wkg\": null,\n    \"duration\": \"4-week double-blind treatment period\"\n  },\n  \"population\": \"Participants with functional dyspepsia (FD) diagnosed with the Rome III criteria in Japan\",\n  \"sample_size\": 54,\n  \"outcomes\": [\n    \"Overall dyspeptic symptom relief rate (5-point Likert scale)\",\n    \"Epigastric pain score\",\n    \"Epigastric burning score\",\n    \"Postprandial fullness score\",\n    \"Early satiation score\"\n  ],\n  \"main_findings\": \"At week 4, overall dyspeptic symptom relief was higher with lansoprazole 15 mg once daily (30.4%) than placebo (6.7%) (p=0.045). Epigastric pain (p=0.045) and epigastric burning (p=0.03) improved significantly versus placebo, while postprandial fullness (p=0.81) and early satiation (p=0.33) did not differ between groups.\",\n  \"effect_direction\": \"benefit\",\n  \"limitations\": [\n    \"Small sample size (n=54)\",\n    \"Short treatment duration (4 weeks)\"\n  ],\n  \"evidence_strength\": \"moderate\",\n  \"confidence\": 0.74,\n  \"peer_reviewed_likely\": \"yes\",\n  \"keywords\": [\n    \"functional dyspepsia\",\n    \"Rome III criteria\",\n    \"lansoprazole\",\n    \"proton pump inhibitor\",\n    \"randomized\",\n    \"double-blind\",\n    \"placebo-controlled\",\n    \"epigastric pain syndrome\"\n  ],\n  \"suggested_hubs\": []\n}"
  },
  "synthesis": null,
  "synthesisStatus": "pending",
  "originalHref": "https://pubmed.ncbi.nlm.nih.gov/24917996/",
  "sourceUrl": "https://rfsafe.org/mel/paper.php?id=3070",
  "updated": "2026-02-13 07:05:54"
}